ESMO 2023 Breast Cancer Highlights – Keynote 756, TROPION-Breast01, Keynote 52

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

In discussion with Dr. Erika Hamilton, covering the ESMO 2023 Breast Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Hamilton:

– Keynote 756 – phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early stage, ER+/HER2- breast cancer, with better pCR seen in pembrolizumab arm

– TROPION-Breast01 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer, with better PFS and ORR favoring Dato-DXd

– Keynote 522 – Event Free Survival update with neoadjuvant and adjuvant pembrolizumab in TNBC, continue to show benefit

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology